Tagtociclib - Pfizer
Alternative Names: PF-07104091; PF-4091; PF-91Latest Information Update: 28 Aug 2025
At a glance
- Originator Pfizer
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Breast cancer; Solid tumours
- Phase I/II Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer
Most Recent Events
- 17 Aug 2025 Pfizer plans a phase I trial in healthy volunteers in Netherlands (PO) in August 2025 (NCT07127770)
- 13 Sep 2024 Efficacy, adverse events, pkarmacokinetics and pharmacodynamics data from a phase I/II trial in Solid tumours presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
- 13 Sep 2024 Pharmacodynamics data from a preclinical trial in Breast cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)